{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:46:42Z","timestamp":1782949602273,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xops.2026.101185","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:15:03Z","timestamp":1775182503000},"page":"101185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-in-Human Clinical Evaluation of a Novel Nonsurgical Suprachoroidal Delivery Approach for Triamcinolone in Diabetic Macular Edema"],"prefix":"10.1016","volume":"6","author":[{"given":"Yoreh","family":"Barak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Mano-Tamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9634-3135","authenticated-orcid":false,"given":"Anastasiia","family":"Adakhovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101185_bib1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","article-title":"Prevalence of diabetic retinopathy in the US in 2021","volume":"141","author":"Lundeen","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101185_bib2","series-title":"IDF Diabetes Atlas","year":"2017"},{"key":"10.1016\/j.xops.2026.101185_bib3","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101185_bib4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101185_bib5","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101185_bib6","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101185_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8289253","article-title":"Pharmacological management of diabetic macular edema in real-life observational studies","volume":"2018","author":"Kodjikian","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.xops.2026.101185_bib8","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101185_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101185_bib10","first-page":"41","article-title":"Intravitreal triamcinolone for intraocular inflammation and associated macular edema","volume":"3","author":"Couch","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101185_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xops.2026.101185_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/jop.2017.0121","article-title":"Intravitreal, subretinal, and suprachoroidal injections: evolution of microneedles for drug delivery","volume":"34","author":"Hartman","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101185_bib13","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101185_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/ph17081007","article-title":"What's new in ocular drug delivery: advances in suprachoroidal injection since 2023","volume":"17","author":"Wu","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.xops.2026.101185_bib15","series-title":"Assessment Report: Luxturna (voretigene neparvovec)","year":"2018"},{"key":"10.1016\/j.xops.2026.101185_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.12.6.3","article-title":"A novel device for suprachoroidal drug delivery to retina: evaluation in Nonhuman Primates","volume":"12","author":"Rotenstreich","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101185_bib17","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.oret.2018.03.008","article-title":"Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK trial","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101185_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xops.2026.101185_bib19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/ph16091241","article-title":"Suprachoroidal injection: a novel approach for targeted drug delivery","volume":"16","author":"Wu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.xops.2026.101185_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/632307","article-title":"Anti-VEGF for the management of diabetic macular edema","volume":"2014","author":"Stefanini","year":"2014","journal-title":"J Immunol Res"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:34:57Z","timestamp":1782948897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666914526001235"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101185","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-Human Clinical Evaluation of a Novel Nonsurgical Suprachoroidal Delivery Approach for Triamcinolone in Diabetic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101185"}}